← All indications
Restless Legs Syndrome
A disorder characterized by aching or burning sensations in the lower and rarely the upper extremities that occur prior to sleep or may awaken the patient from sleep.
Drugs by status
Approved for this indication (4)
Phase 4 trials (9)
Phase 2 trials (18)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (27)
- XenoPort, Inc.
- Astellas
- GlaxoSmithKline
- Neurocare
- Vifor Inc.
- Boehringer Ingelheim
- National Institute on Aging (NIA)
- Augusta University
- Cleveland Sleep Research Center
- Harvard University
- Hoosier Cancer Research Network
- University of South Florida
- University of Bern
- University of Zurich
- Mayo Clinic
- Peking University
- Ospedale Regionale di Lugano
- Ospedale Civico, Lugano
- University of Montpellier
- University of Sao Paulo
- Neurocenter of Southern Switzerland, Lugano
- University of Wisconsin
- Ente Ospedaliero Cantonale
- YRT Limited
- Cardiocentro Ticino
- Johnson and Johnson
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (14)
Organization Involved with Phase 2 Indications (25)
- Ligand Pharmaceuticals
- Impax Laboratories
- Ipsen
- Bioprojet
- Kyowa Hakko Kirin
- Merz
- Neurogen Corporation
- Pharmacosmos
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Johns Hopkins University
- Sleep Health Centers
- Universidad Autonoma de Madrid
- University of Alberta
- University of Bordeaux
- Yale University
- University of Minnesota
- Kyowa Kirin
- Auerbach Hematology and Oncology
- Methodist Cancer Center, Houston, Texas
- AMAG Pharmaceuticals, Inc.
- BioStata
- LabCorp
- Restless Legs Syndrome Foundation
- Hôpital Pellegrin, Bordeaux, FRANCE
Organization Involved with Other Experimental Indications (9)